Abstract: Disclosed is an interactive gaze analysis kit for the early diagnosis of neurodegenerative pathologies essentially composed of a video camera with framing on the eyes of the patient and a screen both connected to a calculation unit through which the user is shown images specifically designed for being able to observe the presence of micronystagmus, the reaction times following an optical stimulations and measure the light sensitivity threshold, through which the diagnosis can be found. Since the test is particularly sensitive to the level of brightness to which the patient is subjected, it is necessary to have the presence of a dark tunnel through which the patient can look at the screen, an infrared, visible spectrum or infrared and visible spectrum lighting system, an image analysis software and input-output peripheral devices for allowing the interaction both with the doctor and with the patient. Other related embodiments are described.

Abstract: The invention relates to blood serum, preferably from umbilical cord blood, for use in the treatment of neurodegenerative pathologies in the ophthalmic field, in particular in the treatment of glaucoma, wherein said serum comprises the nerve growth factor-? (NGF-?) together with other factors, such as, for example, BDNF. The serum can also be used for the treatment of ophthalmologic pathologies whose progression is linked to the activation of neuroinflammatory processes. The invention also relates to a composition comprising said serum and one or more excipients, and/or carriers and/or preservatives acceptable for human use; said composition can for example be in the form of a collyrium. Another aspect of the invention relates to a method for preparing the serum for the use, according to the invention, from blood, preferably from umbilical cord blood.

Abstract: The present invention is directed to a pharmaceutical, dietary and/or food composition comprising saffron for use in the prevention and/or treatment of degenerative eye disorders. The present invention is also directed to a combination comprising saffron and curcumin, and to a pharmaceutical, dietary and/or food composition comprising said combination for use, by oral route, in the prevention and/or treatment of degenerative eye disorders.

Abstract: The present invention relates to a pharmaceutical, dietary and/or food composition, comprising saffron for use in the prevention and/or treatment of corneal dystrophies. The present invention also relates to a combination comprising saffron and at least one antioxidant and to a pharmaceutical dietary and/or food composition comprising said combination for use in the prevention and/or treatment of corneal dystrophies.

Abstract: The present invention relates to a pharmaceutical, dietary and/or food composition, comprising saffron for use in the prevention and/or treatment of corneal dystrophies. The present invention also relates to a combination comprising saffron and at least one antioxidant and to a pharmaceutical dietary and/or food composition comprising said combination for use in the prevention and/or treatment of corneal dystrophies.

Abstract: The present invention is directed to a pharmaceutical, dietary and/or food composition comprising saffron for use in the prevention and/or treatment of degenerative eye disorders. The present invention is also directed to a combination comprising saffron and curcumin, and to a pharmaceutical, dietary and/or food composition comprising said combination for use, by oral route, in the prevention and/or treatment of degenerative eye disorders.